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Background: There are currently few available treatments and no cure for Alzheimer disease 
(AD), a growing public health burden. Animal models and an open-label human trial have 
indicated that deep brain stimulation (DBS) of memory circuits may improve symptoms and 
possibly slow disease progression. The ADvance trial was designed to examine DBS of the 
fornix as a treatment for mild AD.
Methods: ADvance is a randomized, double-blind, placebo-controlled, delayed-start, multi-
center clinical trial conducted at six sites in the US and one site in Canada. Eighty-five sub-
jects initially consented to be screened for the trial. Of these, 42 subjects who met inclusion 
and exclusion criteria were implanted with DBS leads anterior to the columns of the fornix 
bilaterally. They were randomized 1:1 to DBS “off ” or DBS “on” groups for the initial 12 months 
of follow-up. After 1 year, all subjects will have their devices turned “on” for the remainder 
of the study. Postimplantation, subjects will return for 13 follow-up visits over 48 months for 
cognitive and psychiatric assessments, brain imaging (up to 12 months), and safety monitoring. 
The primary outcome measures include Alzheimer’s Disease Assessment Scale – cognitive 
component (ADAS-cog-13), Clinical Dementia Rating sum of boxes (CDR-SB), and cerebral 
glucose metabolism measured with positron emission tomography. This report details the study 
methods, baseline subject characteristics of screened and implanted participants, and screen-
to-baseline test–retest reliability of the cognitive outcomes.
Results: Implanted subjects had a mean age of 68.2 years, were mostly male (55%), and 
had baseline mean ADAS-cog-13 and CDR-SB scores of 28.9 (SD, 5.2) and 3.9 (SD, 1.6), 
respectively. There were no significant differences between screened and implanted or nonim-
planted subjects on most demographic or clinical assessments. Implanted subjects had signifi-
cantly lower (better) ADAS-cog-11 (17.5 vs 21.1) scores, but did not differ on CDR-SB. Scores 
on the major outcome measures for the trial were consistent at screening and baseline.
Conclusion: ADvance was successful in enrolling a substantial group of patients for this novel 
application of DBS, and the study design is strengthened by rigorous subject selection from 
seven sites, a double-blind placebo-controlled design, and extensive open-label follow-up.
Keywords: deep brain stimulation, Alzheimer disease, fornix, methods, clinical trials
Introduction
Alzheimer disease (AD) is the most common neurodegenerative dementia, affecting 
an estimated 5.4 million people1 and costing as much as $214 billion annually in the 
US alone.2 New cases of AD continue to increase at an alarming rate worldwide, 
and its economic and health burden are projected to expand substantially in the next 
50 years.3 Currently, there is no cure for AD. US Food and Drug Administration (FDA)-
approved medications, including three cholinesterase inhibitors and one noncompetitive 
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N-methyl-d-aspartic acid receptor antagonist, temporarily 
ameliorate some symptoms in a subset of patients.1 Phase II 
and III trials of putative disease-modifying therapies targeting 
the amyloid protein aggregations observed in AD have largely 
been unsuccessful in preventing disease progression.4–7 Addi-
tionally, the long-term safety of these treatments remains to 
be determined. Clearly, there is a great need for more specific 
and efficacious therapies for AD.
Converging evidence from neuropathological and in vivo 
imaging studies has demonstrated the vulnerability of the 
hippocampus and heteromodal association cortices in AD, as 
well as decreased functional connectivity in cortico-cortical 
and cortico-hippocampal circuits.8,9 Approaching AD as 
a dysfunction in cortico-cortical and cortico-hippocampal 
circuits suggests that modulating neuronal activity within 
these networks may be a viable treatment option for early 
AD. Deep brain stimulation (DBS) is a neurosurgical tech-
nique that has shown success modulating pain,10 motor 
dysfunction,11,12 and mood13,14 circuits in conditions for which 
pharmacologic treatments are not effective. The importance 
of developing circuitry-based therapeutic approaches to 
modulate cortical and hippocampal networks affected in AD 
was the impetus for a Phase I study of DBS of the fornix in 
early AD patients.15
The fornix is a white matter bundle that connects the 
 hippocampus with other components of the limbic system,16,17 
forming circuits that have been implicated in episodic 
memory.18,19 Recent diffusion tensor imaging (DTI) studies 
have shown white matter reductions in the fornix of indi-
viduals with AD.20 In fact, fornix atrophy may precede both 
hippocampal degeneration and clinical symptoms of AD and 
predict conversion from mild cognitive impairment (MCI) 
to AD.21,22 This growing body of evidence, combined with 
rodent studies showing that DBS of the Papez circuit improves 
memory and promotes neurogenesis,23,24 indicates that DBS 
targeting of the fornix region (DBS-f) may be an effective 
treatment for AD symptoms. In the open-label Phase I trial of 
six AD subjects treated with DBS-f for 12 months, positron 
emission tomography (PET) scans showed an increase in 
cortical glucose metabolism and increased cortical func-
tional connectivity over 1 year15 in contrast to the decreases 
in cortical metabolism and functional connectivity typically 
observed in AD.25–27
Building on the aforementioned collective observations, 
ADvance was designed as a double-blind placebo-controlled 
clinical trial to preliminarily assess the safety and efficacy 
of DBS-f for the treatment of very mild AD, as well as the 
utility of prespecified clinical and neuroimaging baseline 
measures as predictors of response. While other targets 
along the Papez circuit could, at least in theory, be suit-
able or perhaps more optimal, we chose a target within the 
hypothalamus which contains both the descending portion 
of the fornix and the mammillary body. This was done based 
on our empirical observation of acute memory effects in a 
patient with hypothalamic stimulation for obesity28 and the 
preliminary observations in the six AD patients in the pilot 
study of DBS for AD.15 Other potential targets would require 
validation of both safety and efficacy, something that was 
beyond the scope of our trial. Here, we describe the design 
and methods of the ADvance clinical trial and discuss the 
reliability of the major clinical outcome measures used in 
the study.
Methods
Overview
ADvance (ClinicalTrials.gov identifier: NCT01608061) is a 
feasibility clinical trial funded by the National Institute on 
Aging (R01AG042165) and Functional Neuromodulation 
Ltd (FNM). Six sites in the United States and one in Canada 
participated in enrollment (see “Acknowledgments” section). 
Sites were chosen based on previous experience with clinical 
research related to AD, neuroimaging capabilities, ethical 
approvals, and experience with DBS research.
ADvance is a 12-month double-blind, placebo-controlled, 
masked clinical trial, as shown in Figure 1. Consenting 
individuals participated in a screening visit followed by 
a baseline visit to assess eligibility and collect baseline 
cognitive and other clinical assessments, historical docu-
ments, laboratory values, and neuroimaging. DBS device 
implantation took place within 60 days of consent. Two 
weeks following implantation, participants were randomized 
into two groups, DBS “on” or DBS “off ”, for a 12-month 
blinded period followed by a 12-month open-label extension 
during which all subjects will be programmed to DBS “on”. 
Additional long-term clinical follow-up for up to 48 months 
will be provided.
Participants: inclusion  
and exclusion criteria
Inclusion
•	 Informed consent signed by the subject, caregiver, and a 
surrogate
•	 Nonchildbearing/postmenopausal women, and men 
between 45 and 85 years of age
•	 Met criteria for probable AD according to the National 
Institute of Aging/Alzheimer’s Association criteria29
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•	 Clinical Dementia Rating scale (CDR global) rating of 
0.5 or 1 at screening30
•	 Alzheimer’s Disease Assessment Scale – cognitive com-
ponent (ADAS-cog-11) score of 12–24, inclusive, with 
a score $4 on ADAS-cog item 1 (immediate recall) at 
both screening and baseline visits30,31
•	 General medical health rating $3 (good or excellent)32
•	 Living at home with an available caregiver or informant to 
report on daily activities and function throughout the study
•	 Fluent in English
•	 Good surgical candidate for placement of a deep brain 
stimulator, as determined by the neurosurgical team
•	 On a stable dose of a acetylcholinesterase inhibitor 
(AChEI) donepezil, galantamine, or rivastigmine for at 
least 60 days prior to signing informed consent, without 
intention to modify this medication dose throughout the 
entirety of the study.
exclusions
•	 Neuropsychiatric Inventory (NPI)33 total score $10 or 
score $4 in any domain except apathy at screening
•	 Modified Hachinski ischemic score .4 at screening34
•	 Young Mania Rating Scale (YMRS) $11 at screening35
•	 Attempted suicide in the 2 years prior to signing consent
•	 Risk for suicide as determined by an answer of “yes” to 
“suicidal ideation” or “yes” to any items in the suicidal 
behavior section with reference to the 3-month period 
prior to screening on the Columbia Suicide Severity 
Rating Scale (C-SSRS)36
•	 Current major psychiatric disorder
•	 Score .10 on the Cornell Scale for Depression and 
Dementia (CSDD) at screening37
•	 History of head trauma in the 2 years prior to signing 
consent
•	 History of brain tumor, subdural hematoma, or other clini-
cally significant space-occupying lesions on CT (computed 
tomography) or MRI (magnetic resonance imaging)
•	 Mental retardation
•	 Current alcohol or substance use disorder as defined by 
Diagnostic and Statistical Manual of Mental Disorders, 
fourth edition – text revision (DSM-IV-TR)
•	 Exclusions for PET and MRI, including claustrophobia, 
metal implanted in the body (MRI), and insulin- dependent 
diabetes (PET)
•	 Radiation exposure in the year prior to consent that 
added to exposure in the study would exceed 5 rem over 
12 months
•	 Any abnormal laboratory results, cardiovascular or neuro-
vascular disorders, or currently prescribed non-AD medi-
cations that would preclude participation in the study
•	 Unstable doses of any medication prescribed for the 
treatment of memory loss or AD
Prescreening
Screening
(informed consent)
Safety and
interim efficacy
assessments
Key
assessments
safety and
efficacy
Ongoing safety
On
On
OnOnOn
Off Off Off
1, 3, 6, 9 mo
13, 15, 18, 21,
24, 36, 48 mo12 mo
ERC
Enrollment Review Committee
Baseline
(informed consent)
Implantation
n=42
Randomization
day 14
Figure 1 Flow diagram depicting an overview of the Advance trial schedule. Major visits are shown along with the number of participants at implantation (n=42). green 
indicates dBS “on”, red indicates dBS “off ”. 
Abbreviations: mo, months; dBS, deep brain stimulation.
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•	 Unwilling or unable to comply with the protocol
•	 Life expectancy of ,1 year
•	 Actively enrolled in another concurrent clinical trial.
Recruitment and consent
Participants were recruited from memory and geriatric psy-
chiatry clinics, advertising, and community outreach activi-
ties at each of the seven sites. Prospective participants were 
first assessed for their ability to provide consent through clini-
cal interviews. Clinicians experienced in dementia research 
and DBS surgery evaluated each participant’s ability to com-
prehend the consent form as well as understand the personal 
consequences of what would and could happen during the 
study. Assessments and consent procedures took place in the 
presence of a caregiver who cosigned the consent form as a 
witness. Voluntary written informed consent by each subject 
and his or her caregiver was required at the beginning of both 
the screening and baseline visits and prior to surgical implant 
procedure (if all entry requirements were met).
eligibility screening
Enrollment was defined as the time a subject signed the 
screening informed consent to participate and was followed 
by an initial screening visit at which medical and neuropsy-
chiatric information was gathered (Table 1). In order to move 
forward with implantation, a site-independent Enrollment 
Review Committee (ERC) reviewed the data collected to 
determine if subjects met inclusion and exclusion criteria. 
For each subject, the ERC reviewed historical documentation 
of early AD as well as scores on cognitive tests conducted 
during the screening visit to confirm the diagnosis of probable 
AD. They also verified the absence of concomitant medical or 
psychiatric conditions or medications, and any surgical risks 
that might affect DBS surgery. Additionally, US trial sites 
audio-recorded selected psychometric assessments, and site-
independent ERC raters dually scored a randomly selected 
sample of ADAS-cog and CDR interviews to confirm scoring 
accuracy and rater consistency.
Baseline visit and dBS  
device implantation
Baseline visit and surgery
A baseline visit was scheduled #59 days postconsent at 
which baseline medical, laboratory, neuropsychological, and 
imaging data (PET and MRI) were obtained (Table 1).
Implantation surgery took place within 60 days follow-
ing screening consent if all study requirements were met. 
High-resolution, stereotactic MRI scans of the brain were 
used to directly target the bilateral postcommissural fornices. 
More specifically, the DBS electrode was implanted 2 mm 
anterior and parallel to the vertical portion of the fornix 
within the hypothalamus (Figure 2). The most ventral con-
tact of the DBS lead (Medtronic model 3387) was typically 
placed posteromedial to the optic tract at a depth such that 
the dorsal most contact was intraparenchymal, approximately 
at the level of the midcommisural plane. Laterally, the target 
corresponded to the midpoint of the medial/lateral extent of 
the fornix in the coronal plane to maximize the proximity 
of the four DBS contacts to the descending column of the 
fornix. A burr hole was placed approximately 2.5 cm lateral 
to the midline at or just anterior to the coronal suture with 
adjustments made so that the lead trajectory would avoid 
sulci and deflection from the wall of the frontal horn of the 
lateral ventricle. Intraoperative stimulation was performed 
at the discretion of the surgeon to evaluate contact position. 
After surgery and prior to hospital discharge, an MRI was 
conducted to confirm the position of the leads. If necessary, 
the implanting surgeon repositioned the leads during the 
same hospitalization, followed by a second MRI. A third-
party-blinded determination of lead position was obtained 
by sending the postimplant MRI scan to a neurosurgeon not 
involved with surgical implantation of devices for the study, 
who subsequently performed stereotactic analysis of the MRI 
on a DBS planning station.
Surgical devices and programming
The DBS system used in the study includes the Model 37601 
Activa® PC stimulator, Model 3387 Lead, and Model 37085 
extension (Medtronic, Inc., Minneapolis, MS, USA). All 
implantable devices, external control devices, and acces-
sories (Model 8840 N’Vision® programmer with 8870 
Activa  applications software and Model 37022 External 
neurostimulator) are approved by the FDA for DBS treatment 
of Parkinson’s disease and essential tremor. The Activa PC 
neurostimulator (Medtronic, Inc.) is a dual-channel device 
capable of delivering bilateral stimulation. It contains a 
nonrechargeable battery and microelectronic circuitry that 
delivers controlled electrical pulses to specifically targeted 
brain areas. The device was implanted subcutaneously 
just inferior to the clavicle, connected to an extension run 
subcutaneously along the head, neck, and shoulder and 
connected to the implanted leads. Quadripolar DBS leads 
(3387) are made of four thin, insulated coiled wires bundled 
with polyurethane insulation. Each lead has four 1.5 mm 
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Table 1 Advance visit schedule
Screen Baseline Implant Program Months post-DBS device implant
1 3 6 9 12 13* 15* 18* 21* 24* 36* 48*
Procedures
 Consent  
 Review of medication                
 Medical history 
 Physical examination                
 electrocardiogram 
Preoperative lab testsa  
Monitoring lab testsb     
Imaging
 PeT    
 MRI   
Psychiatric consult             
 CSdd           
 yMRS           
 C-SSRS           
Neuropsychological testing
 AdAS-cog           
 CdR          
 NPI          
 CVlT       
 digit span       
 digit symbol       
 Letter fluency       
 Trail Making Test       
 BVMT-R       
 AdCS-Adl23       
 QOl-Ad       
 ZBI       
 hachinski ischemic scale 
dBS device implantation 
Randomization 
device program “on”/“off”  
Unblinding 
Notes: *indicates all the devices programmed “on” for open-label follow-up. Phone follow-up will occur at months 27, 30, 33, 39, 42, 45 to assess adverse events or mood, 
memory, or personality changes. aCBC, INR, PT, PTT, complete metabolic profile; bTSh, free T3, free T4, prolactin, lh, FSh, free testosterone, ACTh, cortisol, glucose, 
complete metabolic profile.
Abbreviations: ACTh, adrenocorticotropic hormone; CBC, complete blood count; AdAS-cog, Alzheimer’s disease Assessment Scale – cognitive component; AdCS-
Adl23, Alzheimer’s disease Cooperative Study – Activities of daily living; BVMT-R, Brief Visuospatial Memory Test – Revised; CdR, Clinical dementia Rating Scale; CSdd, 
Cornell Scale for depression and dementia; C-SSRS, Columbia Suicide Severity Rating Scale; CVlT, California Verbal learning Test; dBS, deep brain stimulation; FSh, 
follicle-stimulating hormone; INR, international normalized ratio; lh, luteinizing hormone; MRI, magnetic resonance imaging; NPI, Neuropsychiatric Inventory; PeT, positron 
emission tomography; PPT, partial prothrombin time; PT, prothrombin time; QOl-Ad, Quality of life – Alzheimer disease; TSh, thyroid-stimulating hormone; yMRS, young 
Mania Rating Scale; T3, free triiodothyronine; T4, free thyroxine; ZBI, Zarit Burden Interview.
electrodes at the tip spaced 1.5 mm apart. Stimulation can be 
delivered using one electrode or a combination of electrodes. 
The N’Vision programmer (8840) is an external component 
that noninvasively reviews and adjusts the neurostimulator’s 
output parameters.
Randomization, blinding, and dBS-f dosing
The overall study design was a delayed-start trial, in which 
all subjects received DBS stimulator implantation and were 
randomly allocated to begin DBS-f soon after implantation or 
1 year later. Patients were randomized 2 weeks after implanta-
tion in a 1:1 allocation to DBS-f “on” or DBS-f “off ”. Ran-
dom blocks were used to generate randomization for each site, 
and the randomization assignment was provided via phone 
call to the unblinded technician responsible for programming 
the implanted device. Study subjects, the implanting surgeon, 
study coordinators, the principal investigator, and follow-up 
clinicians responsible for administering questionnaires and 
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outcome assessments remain blinded to treatment assignment 
until all subjects complete the 12-month visit or until each 
subject’s 24-month visit, whichever occurs first. Instances 
of emergency  unblinding are disclosed to site monitors and 
the national primary investigators (CGL and AML). These 
procedures are only initiated in cases of compromised subject 
welfare and are, whenever possible, reviewed by the national 
and site primary investigators and reported to the commercial 
sponsor (FNM).
At a follow-up visit 11–17 days following surgery, the 
DBS device was programmed according to the randomization 
assignment by an unblinded clinician (Table 1). Starting with 
the most ventral contact, monopolar stimulation was deliv-
ered at a frequency of 130 Hz with a 90-microsecond pulse 
width. The initial amplitude was set to 1 V and was increased 
incrementally by 1 V every 30–60 seconds to a maximum 
until the subject reported experiential phenomena, including 
memory-related phenomena or autonomic symptoms (eg, 
increased heart rate). Each contact was individually tested, 
and the contact on each side that produced an experiential or 
autonomic-related event at the lowest voltage was chosen as 
the therapeutic contact. If no experiential phenomena were 
produced with stimulation, the contact that had the highest 
threshold for autonomic adverse effects was chosen. This 
was usually contact 2 or 3, the two most superior of the four 
contacts on the DBS electrodes. For each subject randomized 
to the DBS-f “on” group, the chosen contact on each side was 
set to a voltage of 50% of that eliciting a stimulation-related 
event or of 3.5 V, whichever was lower. If a stimulation-
related event was reported with bilateral stimulation, the 
voltage was turned down in 0.2 V increments on each lead 
until the event was no longer experienced. For each subject 
randomized to the DBS-f “off ” group, all leads were set 
at 0 V. The programming protocol was completed in full 
regardless of DBS-f “on” or DBS-f “off ” randomization 
status to prevent unblinding of participants, with the only 
difference being the final voltage of the DBS-f electrodes. 
The unblinded clinician at each site is responsible for ensur-
ing that the parameters remain consistent throughout the 
24-month follow-up unless there are stimulation-associated 
side effects or safety concerns. Following the end of the 
24-month follow-up visit, programming will be left to the 
discretion of the site physician.
Follow-up during the double-blind period
Follow-up visits are scheduled for 1, 3, 6, 9, and 12 
months after implantation. These visits include a physical 
examination, psychiatric consultation, neuropsychologi-
cal testing, blood tests (6, 12 months), PET scans (1, 6, 
12 months), and brain MRI (12 months). All subjects, 
including patients randomized to DBS-f “off ”, have the 
implanted device programmed “on” after the 12-month 
visit for a subsequent open-label treatment phase. Open-
label follow-up visits are scheduled for 13, 15, 18, 21, 24, 
36, and 48 months after implantation. These visits consist 
of safety monitoring, clinical updates, physical examina-
tion, psychiatric consultation, and/or neuropsychological 
testing (18, 24 months). There will be additional phone 
follow-ups at months 27, 30, 33, 39, 42, and 45 to assess 
any adverse events (AEs) or changes in cognition or per-
sonality. Subjects will exit the study at the conclusion of 
their 48-month visit (Table 1).
PeT and MRI
MRI and PET protocols were implemented based on the AD 
Neuroimaging Initiative (ADNI) protocols that have been 
used extensively to measure longitudinal changes in gray 
matter volumes (MRI) and cerebral glucose metabolism 
across different MRI and PET scanners and study sites.38,39 
PET scans with the radiotracer [18F]-2-deoxy-2-fluoro-d-
glucose ([18F]-FDG) to measure regional cerebral glucose 
metabolism are acquired preoperatively and at 1, 6, and 
12 months. PET scans are performed on a PET/CT scanner 
at each site using a uniform protocol and postprocessing 
Figure 2 Coronal MRI demonstrating placement of the dBS electrodes anterior and 
parallel to the vertical portion of the fornix within the hypothalamus bilaterally. 
Abbreviation: dBS, deep brain stimulation.
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methods designed to obtain comparable measurements of 
cerebral glucose metabolism across scanners/sites.40 During 
radiotracer uptake, subjects are maintained in a quiet, dimly 
lit room, with eyes open and ears unoccluded. Thirty min-
utes after a 5 mCi ±10% radiotracer injection, patients are 
positioned in the scanner, and a 20-minute emission scan 
is obtained, followed by a transmission scan. The second, 
10-minute frame of the emission scan (40 minutes after 
[18F]-FDG administration) is used for quantitative analysis. 
The MRI protocol was designed to detect focal pathology 
(eg, tumors or strokes) and for MRI-PET registration to 
define regions of interest. The MRI scans were performed 
prior to the first PET scan, 1–2 days postoperatively, and are 
repeated at 12 months. MRI scans are acquired on 1.5 T scan-
ners at each site. The sequences were implemented from the 
ADNI protocols that were developed for each MRI scanner 
to obtain comparable quantitative measurements, including 
gray matter volumes.38,39 The MRI sequences include 3-plane 
localizer, volumetric sequence (magnetization-prepared 
rapid gradient-echo or spoiled gradient recalled echo), T
2
 
sequences for electrode localization (postoperative scan 
only), fast spin-echo inversion recovery (FSE-IR), DTI 
(when available), and resting-state functional MRI (when 
available).
Safety monitoring
An independent Clinical Events Committee (CEC) consist-
ing of a multidisciplinary team of physicians from geriatrics, 
neurology, and neurosurgery who are not investigators in 
the study was created. The CEC conducts reviews of all 
AEs reported for study subjects. Each AE is adjudicated for 
its relatedness to the study, surgical procedure, implantable 
pulse generator, leads (electrodes), and programming. AEs 
are categorized as general medical, psychiatric, surgical, or 
programming in nature. In addition, adjudications are made 
regarding whether an event is a serious AE or an unantici-
pated adverse device effect. Psychiatric AEs are assessed at 
each follow-up visit using measures such as the C-SSRS,36 
CSDD,37 and YMRS.35
A separate independent Data Safety and Monitoring 
Board (DSMB) of one practicing neurosurgeon, two neu-
rologists and/or psychiatrists, and one biostatistician not 
connected to the sponsor or participating investigators was 
established. The DSMB reviews CEC-adjudicated AEs, 
occurrences of serious AEs and unanticipated adverse device 
effects, as well as safety and efficacy trends and makes 
recommendations regarding the continuation, suspension, 
or termination of the study. Following each review by the 
DSMB, a summary of results is sent to the FDA and filed 
with all overseeing institutional review boards.
Outcome measures and analytic plan
Safety outcome assessment
Doctors and clinical staff at local sites are in regular contact 
with participants and study partners to monitor for AEs, as 
described earlier. As soon as an AE is detected, the local 
team obtains as much clinical information as possible and 
rapidly reports to the study principal investigator, the medi-
cal monitor, and the coordinating center. The coordinating 
center, working as a team, then reviews, requests additional 
information, notifies other sites, and notifies DSMB, insti-
tutional review boards, and FDA as spelled out in study 
procedures. AEs will be presented as a measure of the safety 
of DBS-f surgery and treatment for mild AD.
Clinical outcome assessment
One primary goal of this study is to examine the acute and 
long-term safety of DBS-f for mild AD. Acute safety is 
assessed by the rate of serious device- or procedure-related 
AEs from the date of implant through the date of random-
ization as well as serious procedure-related events through 
30 days postimplant. Long-term safety is assessed by the rate 
of serious therapy (programming) related AEs from the date 
of randomization through the date of the 12-month visit.
The second goal of this study is to preliminarily examine 
the efficacy of DBS-f for mild AD. The two primary outcomes 
are change from baseline in the ADAS-cog and CDR sum of 
boxes (CDR-SB) scores. The ADAS-cog is one of the more 
commonly used measures to assess cognitive symptoms 
associated with AD in clinical trials. The ADAS-cog is able 
to differentiate individuals with nonimpaired cognition 
from those with impaired cognition and has demonstrated 
reliability in assessing the extent of cognitive impairment in 
individuals.41 The standard ADAS-cog consists of 11 sub-
scales designed to assess memory, language, and praxis, and 
scoring is based on the number of errors made on each item, 
with a higher score indicating greater impairment. Previous 
clinical trials have indicated that a four-point change on the 
ADAS-cog total score is suggestive of a clinically important 
difference.42,43 However, systematic analysis of double-blind 
placebo-controlled trials of cholinesterase inhibitors dem-
onstrated an average -2.7 improvement at 6 months and 1 
year.44 The CDR was developed for the evaluation of staging 
severity of dementia.45 The CDR characterizes cognitive 
and functional performance by assessing the subject in six 
domains including memory, orientation, and problem solving. 
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The CDR has consistently demonstrated good reliability46,47 
and has been validated against neuropathological findings.48,49 
A global CDR score is computed via an algorithm based 
on the input of the ratings of the six domains and is useful 
for characterizing and tracking a subject’s level of impair-
ment and stage of dementia severity,45 with values between 
0 (normal) and 3 (severe dementia). The CDR-SB score is 
obtained by summing each of the six domain  ratings. CDR-
SB scores range from 0 to 18, with higher scores reflecting 
more severe impairment.46
Secondary outcomes include change from baseline to 
12 months in scores on other cognitive tests: California Verbal 
Learning Test, second edition (CVLT-II50);  Verbal Fluency;51 
Brief Visuospatial Memory Test – revised version;52 and Trail 
Making Test.53 Other measures include Quality of Life – AD, 
which is a rating of the patient’s quality of life both from the 
patient and the caregiver,54 AD Cooperative Study – Activi-
ties of Daily Living Inventory, Zarit Burden Interview to 
assess caregiver distress,55 and NPI to assess the presence 
of psychiatric symptoms and behaviors.33
Neuroimaging outcome assessment
The primary neuroimaging outcome measure is a regional 
change in glucose metabolism from baseline to 12 months, 
measured by PET. Previous research using PET measures 
of cerebral glucose metabolism has identified a specific pat-
tern in AD of hypometabolism in the parietal and temporal 
heteromodal association cortices.56 This pattern has been 
found in over 85% of pathologically confirmed AD cases56 
and has been correlated with dementia severity.56 FDG-PET 
is sensitive to AD clinical progression and to effects of phar-
macotherapy, including DBS.15,26,57–59
A secondary imaging outcome is bilateral hippocampal 
volume measured using volumetric methods, decreases in 
which have been correlated with the progression of AD.21,22 An 
additional imaging tool of interest is fornix integrity measured 
with DTI for which the fornix is manually drawn (with high 
reliability) as a region of interest. However, we do not plan 
to use DTI obtained after implantation analytically due to 
concerns about interference by the implanted electrodes.
Clinical measure analytic plan
All analyses will be conducted according to the prespecified 
statistical analysis plan for the study. Descriptive statis-
tics compare treatment group on baseline demographics. 
 Categorical variables are analyzed using frequency, inci-
dence, and event rate. For continuous variables, analyses 
include mean, median, standard deviation, and range.
For the acute safety end point, rate and 95% confidence 
interval will be presented. For long-term safety end points, 
rate and 95% confidence interval will be compared according 
to randomization group. Other data summaries will include 
a detailed summary and rate estimation of all serious AEs, 
as well as Kaplan–Meier estimates of the cumulative rates 
over time.
For the two clinical efficacy outcomes of particular 
interest (ADAS-cog score and CDR score), all analyses 
will follow intent-to-treat (ITT) or modified-ITT principles. 
The mean change from baseline (preimplant) to 12 months 
postimplant will be calculated in each group. Differences 
between randomized groups in mean change on each of 
these primary outcomes will be calculated, along with cor-
responding two-sided 95% confidence intervals. In addition, 
within group improvements will be assessed relative to a null 
change of zero. Additional analyses will include assessments 
of change over time in mixed model regression estimations 
with repeated measurements. Site will be used as a covariate 
in this model.
In addition to ADAS-cog-13 total score, this method will 
also be used to examine derived Word Recall Total score, 
Word Recognition scores, and the subset of five ADAS-cog 
items shown to be most sensitive to memantine. The subset-
ting methodology described by Ihl et al60 will be applied to 
this data set to assess the relative strength of treatment effect 
across other subtests of the ADAS-cog. Further analyses will 
be conducted to determine the impact of baseline ADAS-cog 
scores on outcome (ie, to assess whether the treatment effect 
diminishes in the more advanced population), including 
mixed model regression analyses with baseline ADAS-cog 
score as a predictor, and fit with an interaction term. Within-
group outcomes, by baseline ADAS-cog score also will be 
summarized. CDR analyses will include global score, SB, 
and memory domain score. In addition we will analyze the 
CDR-SB score relative to the overall severity classification 
from the ADAS-cog to determine the agreement of catego-
rization of mild symptom severity at baseline with how the 
scores change together over time.
Neuroimaging measure analytic plan
The end point is the mean, per-subject, percent glucose metab-
olism change in prespecified regions of interest, including the 
subdivisions of the temporal and parietal association cortex and 
the hippocampus. The primary analysis will be conducted on 
an ITT basis. The percent improvement for each subject will 
be determined by subtracting the baseline value for glucose 
metabolism in each region of interest (ROI-BL) from the 
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12-month glucose metabolism (ROI-12) and dividing the result 
by ROI-BL ([ROI-12 - ROI-BL]/ROI-BL). This quantity will 
be averaged across all subjects, and mean improvement will be 
compared across randomization groups in a two-sample t-test 
evaluated at the 0.05 significance level. Supportive analyses 
will only evaluate those subjects with complete data and/or 
those who are compliant with the protocol.
Exploratory analyses will be conducted to evaluate the 
relationship between changes in regional glucose metabolism 
and changes in clinical outcomes (eg, ADAS-cog, CVLT, etc). 
Exploratory analyses will be performed to identify baseline 
structural and functional neuroimaging predictors of DBS 
clinical response. These analyses may include, but not be lim-
ited to, regional glucose metabolism, hippocampal volumes, 
and regional white matter functional integrity (DTI). These 
analyses will fit multivariate linear regression models, with the 
candidate predictor and randomization assignment, and their 
interaction as independent variables, and clinical outcome (eg, 
ADAS-cog-11, CDR-SB, CVLT) as the dependent variable. 
Covariates with apparent effect on outcome will then be fit 
in a multivariate regression model with stepwise selection 
procedure using significance level of 0.10 as a cutoff.
Power estimation
The power to detect a treatment effect depends on the size of 
the effect, sample size, and the configuration of the within-
person variance–covariance matrix. For the ADAS-cog, we 
conducted a power simulation using ADNI data. Assuming 
a mixed effects model with random intercept and slope, no 
missing data, variance of intercept =(4.68)2, variance of 
slope =(0.37)2, correlation between random intercept and 
random slope of 0 (model with unstructured covariance 
failed to converge), variance of residuals =(5.87)2, time 
vector = c (0,3,6,9,12), there is 84% power to detect a dif-
ference in change scores of 7.53 points with 42 subjects, 
which translates to a difference in slopes of 0.63. We will 
have 80% power to detect a difference in slope of 0.588 
points/month or 7.06 points/year. Using the same method, 
the power to detect a difference in a change of score of 4.0 
points (a typical effect size) was calculated to be 36%, which 
translates to a difference in slopes of 0.33.
Statistical power for the neuroimaging hypothesis listed 
previously was estimated using PASS 2008 software under 
a two-sided, two-sample t-test and the assumption of 40 ran-
domized subjects in a 1:1 allocation. Assuming a significance 
level (α) of 5%, mean improvement (DBS) of 10%, standard 
deviation (DBS and control) of 12%, and mean improvement 
(control) of 0.0%, a total of 40 randomized subjects provides 
at least 80% power to statistically evaluate the end point of 
glucose metabolism as specified earlier.
Results
Characterization of the baseline  
study population
Following recruitment, 85 potential subjects across the 
seven study sites signed the initial consent and participated 
in a screening visit. Forty-eight (56.5%) met all inclusion 
and exclusion criteria at screening and were approved by 
ERC reviewers to proceed in the trial. Forty-two of these 
48 patients (49.4% of consenting potential subjects) met all 
criteria following the baseline visit, signed a second con-
sent form, and underwent DBS-f device implantation. The 
six patients who were cleared at screening but did not proceed 
to implant did so for two reasons: two declined to proceed 
and did not sign consent for baseline testing, and four failed 
to meet inclusion/exclusion criteria when ADAS-cog was 
repeated at baseline, with scores out of range.
We compared (Table 2) consenting subjects who were 
screened and successfully implanted (N=42) to those who 
were screened but not implanted with a DBS device (N=43). 
We saw no difference between these groups in demographic 
information (age, sex, and elapsed time since initial AD diag-
nosis) gathered at screening. We observed significantly lower 
(ie, better) ADAS-cog-11 (17.5±3.6 vs 21.1±9.8, P=0.03) and 
CDR global scores (67% vs 38%, with a score of 0.5, P=0.05) 
in subjects who were implanted. This is explained by the inclu-
sion and exclusion criteria designed to limit participation to 
subjects with very mild AD. Approximately 40% of patients 
who failed screening did so because symptom severity was too 
high. No significant difference was found in CDR-SB score, 
Hachinski ischemic scale score, or psychiatric assessment 
measures, including the NPI, C-SSRS, CSDD, or the YMRS 
in implanted compared to not implanted patients (Table 2).
Table 2 summarizes the scores of implanted subjects on 
additional cognitive and psychiatric tests from the baseline 
visit. In addition to inclusion criteria measures such as the 
CDR, scores on the CVLT-II, a verbal memory measure, were 
similar to published scores of individuals with MCI who later 
progressed to AD.61 Note that these additional scores include 
all 48 subjects who were assessed at baseline, not only the 
42 who were implanted.
Reliability of primary outcome measures
We examined test–retest reliability of the main outcome 
measures by comparing score stability between the screening 
and baseline visits for the 42 implanted subjects. There was 
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a moderate correlation between screening and baseline visit 
scores for ADAS-cog-11 and a high correlation for ADAS-
cog-13, CDR global score, CDR-SB, and NPI (Table 3). The 
stability in scores seen within subjects across initial visits 
suggests that our primary clinical outcome measures are 
reliable for the population in this study and can be used to 
measure disease progression over time in this trial.
Discussion
ADvance is the first multicenter, randomized, double-blind 
controlled clinical trial evaluating the efficacy of DBS-f 
for mild AD. This paper outlines the methods used in the 
ADvance trial and characterizes the study population. 
Subjects demonstrate cognitive test scores indicative of mild 
AD, and implanted participants differ from consenting non-
implanted participants only on average ADAS-cog-11 and 
CDR global scores. Furthermore, we confirm the reliability 
of the primary outcome measures used in the ADvance study 
population by demonstrating consistency across two visits.
ADvance joins three smaller DBS studies conducted in 
AD patients published thus far62 and builds on data from 
approximately 25 animal studies.23,24,28,63 ADvance was 
designed based on an open-label Phase I study of DBS-f 
conducted in six patients with mild AD, as previously 
discussed. Interestingly, patients with less severe prestimula-
tion cognitive dysfunction and less severe metabolic deficits 
were more likely to benefit from DBS-f in this trial.15 This 
study provided the basis for the inclusion criteria used in 
ADvance, which focus on selection of participants with very 
mild AD. Implanted participants were younger, more likely 
to be male, and had lower baseline ADAS-cog-11 scores 
than the mean scores in recently reported Phase III trials of 
amyloid-lowering agents in AD.64–66 Mean ADAS-cog-11 was 
17.5 for implanted ADvance participants, and ranged from 
19 to 23 in recent Phase III trials. Thus, our participants were 
younger and less impaired than those in these Phase III trials, 
but the differences were relatively small.
Fontaine et al67 recruited 110 patients with Alzheimer 
dementia or MCI to be screened for a study assessing 
DBS for cognitive decline, and one subject met criteria, 
consented, and continued on to implantation. In the current 
study, 42 of 85 screened subjects consented and underwent 
implantation. One possible explanation for this difference 
may be that the Fontaine et al67 study required subjects 
to have received a DSM-IV AD diagnosis within 2 years 
and have a mini–mental state examination score between 
20 and 24, which was not required in the ADvance study. 
It also is possible that the 1-year open-label follow-up 
phase used in ADvance may have contributed to improved 
participation.
Table 2 demographics and screening measures by implantation 
status
Patient  
characteristic
Screened and 
implanted 
(n=42)
Screened and 
not implanted 
(n=43)
P-value*
Age (years) 68.2±7.8 66.8±7.4 0.41
Sex (male) 55% 47% 0.45
elapsed time since initial 
diagnosis of Ad (years)
2.5±1.9 1.6±1.4 0.06
AdAS-cog-11 score 17.5±3.6 21.1±9.8 0.03
AdAS-cog-13 score 28.9±5.2 32.3±11.4 0.08
CdR global score: 0.5 67% 38% 0.05
CdR global score: 1 33% 57%
CdR global score: 2 5%
CdR sum of boxes  
score
3.9±1.6 4.5±2.3 0.30
NPI total score 2.8±2.8 4.7±7.1 0.12
hachinski ischemic  
scale score
0.5±0.6 0.4±0.5 0.34
C-SSRS score 0.2±0.8 0.3±0.7 0.74
CSdd score 1.8±2.1 2.2±3.6 0.54
yMRS score 0.18±0.58 0.16±0.50 0.89
gMhR scorea 3.9±0.3 NA
CVLT-II – sum of first  
five recall trials Aa
20.3±9.1 NA
CVlT-II – short delay  
free recall Aa
1.9±1.9 NA
CVlT-II – short delay  
free recall Ca
3.6±2.5 NA
CVlT-II – long delay  
free recall Aa
1.5±2.2 NA
AdCS-Adl23 scorea 69.5±6.0 NA
Notes: *P-values for continuous measure calculated by t-tests; P-values for discrete 
measures calculated by chi-squared tests; adata gathered at baseline visit.
Abbreviations: Ad, Alzheimer’s disease; AdAS-cog, Alzheimer’s disease 
Assessment Scale – cognitive component; AdCS-Adl23, Alzheimer’s disease 
Cooperative Study – Activities of daily living; CdR, Clinical dementia Rating 
Scale; NPI, Neuropsychiatric Inventory; CSdd, Cornell Scale for depression and 
dementia; C-SSRS, Columbia Suicide Severity Rating Scale; CVlT-II, California 
Verbal learning Test, second edition; gMhR, general Medical health Rating score; 
NA, not applicable; yMRS, young Mania Rating Scale.
Table 3 Correlation* between screening and baseline value
Measure N Pearson’s 
correlation
Intraclass 
correlation
Kappa
AdAS-cog-11 score 42 0.42 0.41
AdAS-cog-13 score 42 0.54 0.51
CdR global score 42 0.68
CdR sum of boxes score 42 0.68 0.69
NPI total score 42 0.59 0.60
Notes: *The kappa statistic is reported for the CdR global score; the Pearson and 
intraclass correlation coefficients are reported for all the other measures.
Abbreviations: AdAS-cog, Alzheimer’s disease Assessment Scale – cognitive 
component; CdR, Clinical dementia Rating scale; NPI, Neuropsychiatric Inventory.
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Another study in 2014 examined open-label DBS targeting 
the nucleus basalis of Meynert in six patients meeting criteria 
for mild-to-moderate AD. Although ADAS-cog scores wors-
ened by an average of 3 points after 1 year of stimulation, the 
authors noted that this was less than the average 6- to 7-point 
worsening seen in prior reports of patients with AD. Further, 
global increases in metabolism in amygdalohippocampal and 
temporal regions were seen in three out of the four patients who 
underwent PET scans of cerebral glucose metabolism.68
Taken in the context of prior research, ADvance is a novel, 
important step in studying DBS-f as a treatment for mild 
AD. The subject pool is much larger than prior studies and 
involves 1 year of double-blind, controlled cognitive testing 
and neuroimaging. The 1-year duration of the controlled 
comparison increases the likelihood of identifying significant 
differences between the stimulated (treatment arm) and non-
stimulated (control arm) cohorts in this slowly progressive 
disorder. The 1-year blinded, controlled phase of the study is 
followed by up to 3 years of continued open-label follow-up 
with all patients being stimulated, which affords system-
atic pre- and postassessment of outcomes in about half the 
participants, and 2 years of additional follow-up. While the 
primary objective of the study is to evaluate safety, the larger 
subject population and controlled design affords preliminary 
testing of the efficacy of DBS-f in delaying cognitive decline 
and improving cortical glucose metabolism.
The ADvance methodology outlined here is strengthened 
by recruitment from seven sites with experienced investiga-
tors and rigorous subject selection by an independent ERC. 
The primary clinical outcome measures are standardized and 
validated and have been widely used so that the results of the 
current study can be evaluated in comparison to studies that 
tested other symptomatic treatments such as cholinesterase 
inhibitors.69 The neuroimaging outcome measures, especially 
cerebral glucose metabolism, have also been well studied in 
AD56,57,70,71 and enable us to examine changes in brain func-
tion throughout the trial. Limitations of ADvance include 
limited sample size. Although larger than prior DBS studies, 
there are only 21 patients in each of the masked treatment 
groups. The goal is that the results of ADvance will inform a 
larger-scale clinical trial focused primarily on efficacy, rather 
than on safety, of DBS-f as a treatment for mild AD.
Research elucidating the neurobiological mechanism 
of DBS treatment for neurodegenerative diseases such as 
AD remains limited. While we hypothesize that this treat-
ment works by stimulation of fornix–hippocampal–cortical 
circuits, and potentially even promotes neurogenesis in the 
hippocampus, this remains unproven. The memory circuits 
we are examining may be undergoing degeneration at 
varying rates in individual study participants, limiting the 
effectiveness of DBS-f to slow cognitive decline and our 
ability to examine the efficacy of DBS-f within our study 
population.
In summary, the ADvance trial was successful in enroll-
ing appropriate patients for a novel application of DBS, and 
we believe several unique design aspects outlined here could 
be considered in future clinical trials of DBS targeting AD 
and other cognitive disorders.
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